Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Association of thiazolidinediones with gastric cancer in type 2 diabetes mellitus: a population-based case–control study

Authors: Shen-Shong Chang, Hsiao-Yun Hu

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

It has been shown that peroxisome proliferator-activated receptors (PPAR) have physiological and pharmacological ligands. The objective is to assess the association between thiazolidinediones (TZDs) and the occurrence of gastric cancer.

Methods

We conducted a population-based nested case–control study. Data were retrospectively collected from the National Health Insurance Research Database (NHIRD). The cases consisted of all diabetes mellitus (DM) patients aged 30 to 99 years, and who had a first time diagnosis of gastric cancer in the study cohort. The controls were matched to cases by age, sex, and index date. The adjusted odds ratio (OR) and 95% confidence interval (CI) were estimated by using multiple logistic regression.

Results

Records from 357 gastric cancer and 1,428 selected matched controls were included in the analyses of gastric cancer risk. A total of 7% or 9.5% of the cases and 10.8% or 14.8% of the controls had used any quantity of at least 2 prescriptions for pioglitazone or rosiglitazone, respectively. After adjusting for possible confounders, pioglitazone (OR = 0.93, P > 0.05) and rosiglitazone (OR = 1.21, P > 0.05), had no significant association of decreasing gastric cancer. After adjusting for possible confounders, pioglitazone (OR = 0.70, P > 0.05) or rosiglitazone (OR = 0.79, P > 0.05), had no significant trend toward decreasing gastric cancer risk with increasing cumulative doses ≥ 260 defined daily doses (DDDs), respectively. Moreover, adjusting for possible confounders pioglitazone (OR = 0.68, P > 0.05) or rosiglitazone (OR = 0.74, P > 0.05) had no significant trend toward decreasing gastric cancer risk with increasing cumulative doses ≥ 1 year, respectively.

Conclusions

Our results did not show evidence to support that TZD derivatives in DM patients reduces gastric cancer occurrence.
Literature
1.
Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001, 94: 153-156. 10.1002/ijc.1440.CrossRefPubMed
2.
Nicolucci A: Epidemiological aspects of neoplasms in diabetes. Acta Diabetol. 2010, 47: 87-95. 10.1007/s00592-010-0187-3.CrossRefPubMed
3.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 2009, 59: 225-249. 10.3322/caac.20006.CrossRefPubMed
4.
Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, Gaziano JM, Pollak M, Stampfer MJ: Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 2008, 9: 1039-1047. 10.1016/S1470-2045(08)70235-3.CrossRefPubMedPubMedCentral
5.
Kushi LH, Byers T, Doyle C, Bandera EV, McCullough M, McTiernan A, Gansler T, Andrews KS, Thun MJ, American Cancer Society 2006 Nutrition and Physical Activity Guidelines Advisory Committee: American cancer society guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2006, 56: 254-281. 10.3322/canjclin.56.5.254.CrossRefPubMed
6.
Secretan B, Straif K, Baan R, Grosse Y, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V, WHO International Agency for Research on Cancer Monograph Working Group: A review of human carcinogens–Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol. 2009, 10: 1033-1034. 10.1016/S1470-2045(09)70326-2.CrossRefPubMed
7.
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D: Diabetes and cancer: a consensus report. Diabetes Care. 2010, 33: 1674-1685. 10.2337/dc10-0666.CrossRefPubMedPubMedCentral
8.
Willson TM, Brown PJ, Sternbach DD, Henke BR: The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000, 43: 527-550. 10.1021/jm990554g.CrossRefPubMed
9.
Theocharis S, Margeli A, Vielh P, Kouraklis G: Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators. Cancer Treat Rev. 2004, 30: 545-554. 10.1016/j.ctrv.2004.04.004.CrossRefPubMed
10.
Kersten S, Desvergne B, Wahli W: Roles of PPARs in health and disease. Nature. 2000, 405: 421-424. 10.1038/35013000.CrossRefPubMed
11.
Panigrahy D, Shen LQ, Kieran MW, Kaipainen A: Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin Investig Drugs. 2003, 12: 1925-1937. 10.1517/13543784.12.12.1925.CrossRefPubMed
12.
Martelli ML, Iuliano R, Le Pera I, Sama’ I, Monaco C, Cammarota S, Kroll T, Chiariotti L, Santoro M, Fusco A: Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. J Clin Endocrinol Metab. 2002, 87: 4728-4735. 10.1210/jc.2001-012054.CrossRefPubMed
13.
Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP: Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A. 1998, 95: 8806-8811. 10.1073/pnas.95.15.8806.CrossRefPubMedPubMedCentral
14.
Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T: Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab. 2001, 86: 2170-2177. 10.1210/jc.86.5.2170.PubMed
15.
Rumi MA, Sato H, Ishihara S, Kawashima K, Hamamoto S, Kazumori H, Okuyama T, Fukuda R, Nagasue N, Kinoshita Y: Peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition of human hepatocellular carcinoma. Br J Cancer. 2001, 84: 1640-1647. 10.1054/bjoc.2001.1821.CrossRefPubMedPubMedCentral
16.
17.
Giaginis C, Theocharis S, Tsantili-Kakoulidou A: A consideration of PPAR-gamma ligands with respect to lipophilicity: current trends and perspectives. Expert Opin Investig Drugs. 2007, 16: 413-417. 10.1517/13543784.16.4.413.CrossRefPubMed
18.
Lu J, Imamura K, Nomura S, Mafune K, Nakajima A, Kadowaki T, Kubota N, Terauchi Y, Ishii G, Ochiai A, Esumi H, Kaminishi M: Chemopreventive effect of peroxisome proliferator-activated receptor gamma on gastric carcinogenesis in mice. Cancer Res. 2005, 65: 4769-4774. 10.1158/0008-5472.CAN-04-2293.CrossRefPubMed
19.
Takahashi N, Okumura T, Motomura W, Fujimoto Y, Kawabata I, Kohgo Y: Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett. 1999, 455: 135-139. 10.1016/S0014-5793(99)00871-6.CrossRefPubMed
20.
Konturek PC, Kania J, Kukharsky V, Raithel M, Ocker M, Rembiasz K, Hahn EG, Konturek SJ: Implication of peroxisome proliferator-activated receptor gamma and proinflammatory cytokines in gastric carcinogenesis: link to Helicobacter pylori-infection. J Pharmacol Sci. 2004, 96: 134-143. 10.1254/jphs.FPJ04016X.CrossRefPubMed
21.
Jick H, Garcia Rodriguez LA, Perez-Gutthann S: Principles of epidemiological research on adverse and beneficial drug effects. Lancet. 1998, 352: 1767-1770. 10.1016/S0140-6736(98)04350-5.CrossRefPubMed
22.
Essebag V, Platt RW, Abrahamowicz M, Pilote L: Comparison of nested case–control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol. 2005, 5: 5-10.1186/1471-2288-5-5.CrossRefPubMedPubMedCentral
23.
WHO Collaborating Center for Drugs Statistics Methodology: ATC Index with DDDs 2003. 2003, Oslo: WHO
24.
Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, Chan KA: Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology. 2012, 55: 1462-1472. 10.1002/hep.25509.CrossRefPubMed
25.
Hsiao FY, Tsai YW, Wen YW, Kuo KN, Tsai CR, Huang WF: Effect of helicobacter pylori eradication therapy on risk of hospitalization for a major ulcer event. Pharmacotherapy. 2011, 31: 239-247. 10.1592/phco.31.3.239.CrossRefPubMed
26.
Batal HA, Krantz MJ, Dale RA, Mehler PS, Steiner JF: Impact of prescription size on statin adherence and cholesterol levels. BMC Health Serv Res. 2007, 7: 175-10.1186/1472-6963-7-175.CrossRefPubMedPubMedCentral
27.
Leung WK, Bai AH, Chan VY, Yu J, Chan MW, To KF, Wu JR, Chan KK, Fu YG, Chan FK, Sung JJ: Effect of peroxisome proliferator activated receptor gamma ligands on growth and gene expression profiles of gastric cancer cells. Gut. 2004, 53: 331-338. 10.1136/gut.2003.021105.CrossRefPubMedPubMedCentral
28.
Cheon CW, Kim DH, Cho YH, Kim JH: Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009, 15: 310-320. 10.3748/wjg.15.310.CrossRefPubMedPubMedCentral
29.
Jiang C, Ting AT, Seed B: PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998, 391: 82-86. 10.1038/34184.CrossRefPubMed
30.
Rodriguez-Calvo R, Serrano L, Coll T, Moullan N, Sanchez RM, Merlos M, Palomer X, Laguna JC, Michalik L, Wahli W, Vazquez-Carrera M: Activation of peroxisome proliferator-activated receptor beta/delta inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor-kappaB activity via extracellular signal-related kinase 1/2. Diabetes. 2008, 57: 2149-2157. 10.2337/db08-0176.CrossRefPubMedPubMedCentral
31.
Slomiany BL, Slomiany A: Suppression of gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide by peroxisome proliferator-activated receptor gamma activation. IUBMB Life. 2002, 53: 303-308. 10.1080/15216540213459.CrossRefPubMed
32.
Gupta RA, Polk DB, Krishna U, Israel DA, Yan F, DuBois RN, Peek RM: Activation of peroxisome proliferator-activated receptor gamma suppresses nuclear factor kappa B-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells. J Biol Chem. 2001, 276: 31059-31066. 10.1074/jbc.M104141200.CrossRefPubMed
33.
Talley NJ, Fock KM, Moayyedi P: Gastric Cancer Consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. Am J Gastroenterol. 2008, 103: 510-514. 10.1111/j.1572-0241.2008.01819.x.CrossRefPubMed
34.
Wu CY, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT: Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology. 2009, 137: 1641-1648. 10.1053/j.gastro.2009.07.060.CrossRefPubMed
35.
Kuo HW, Tsai SS, Tiao MM, Liu YC, Lee IM, Yang CY: Analgesic use and the risk for progression of chronic kidney disease. Pharmacoepidemiol Drug Saf. 2010, 19: 745-751. 10.1002/pds.1962.CrossRefPubMed
36.
Ma XM, Yu H, Huai N: Peroxisome proliferator-activated receptor-gamma is essential in the pathogenesis of gastric carcinoma. World J Gastroenterol. 2009, 15: 3874-3883. 10.3748/wjg.15.3874.CrossRefPubMedPubMedCentral
Metadata
Title
Association of thiazolidinediones with gastric cancer in type 2 diabetes mellitus: a population-based case–control study
Authors
Shen-Shong Chang
Hsiao-Yun Hu
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-420

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Measurement of tumour size with mammography, sonography and magnetic resonance imaging as compared to histological tumour size in primary breast cancer

Research article

Overexpression of heat shock transcription factor 1 enhances the resistance of melanoma cells to doxorubicin and paclitaxel

Research article

Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme

Research article

IL-11 produced by breast cancer cells augments osteoclastogenesis by sustaining the pool of osteoclast progenitor cells

Research article

Post-diagnosis hemoglobin change associates with overall survival of multiple malignancies – results from a 14-year hospital-based cohort of lung, breast, colorectal, and liver cancers

Research article

Estimating the lifelong health impact and financial burdens of different types of lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits